Skip to main content
BRAIN Biotech AG logo

BRAIN Biotech AG — Investor Relations & Filings

Ticker · BNN ISIN · DE0005203947 LEI · 391200JKPVHLD6JLZ107 F Professional, scientific and technical activities
Open in API
Filings indexed 368 across all filing types
Latest filing 2022-11-17 Major Shareholding Noti…
Country DE Germany
Listing F BNN

About BRAIN Biotech AG

https://www.brain-biotech.com/

BRAIN Biotech AG is an industrial biotechnology company specializing in the discovery, development, and production of specialty enzymes, high-performance microorganisms, and bioactive compounds. The company provides tailor-made biosolutions and contract research and development (R&D) services to partners in the food, chemical, and life sciences sectors. Core competencies include enzyme technology, microbial strain development, and bioprocess development. By leveraging an advanced technology portfolio, which includes proprietary platforms for enzyme discovery and genome editing, the company enables its partners to create more sustainable and efficient industrial products and processes, contributing to the bioeconomy.

Recent filings

Filing Released Lang Actions
BRAIN Biotech AG: MP Beteiligungs-GmbH Increases Stake in BRAIN Biotech AG
Major Shareholding Notification Classification · 99% confidence The document is a news release disseminated via EQS-News, dated November 17, 2022. The core content announces that MP Beteiligungs-GmbH increased its stake in BRAIN Biotech AG to approximately 45% following a block transaction. This concerns a change in significant share ownership by an existing investor. This aligns directly with the definition for Major Shareholding Notification (MRQ), which covers notifications of changes in significant share ownership levels crossing thresholds. It is not an Earnings Release (ER), a Director's Dealing (DIRS), or a general Regulatory Filing (RNS), as it specifically details a change in a major shareholder's stake.
2022-11-17 English
BRAIN Biotech and Bonumose collaborate on enzymes for the production of rare monosaccharides
Regulatory Filings Classification · 99% confidence The document is a press release dated October 25, 2022, announcing a strategic collaboration between BRAIN Biotech AG and Bonumose regarding enzyme optimization for rare sugar production. It uses the header 'EQS-News' and discusses business developments, milestones, and company updates, rather than presenting formal financial statements (like 10-K or IR) or specific voting results. This type of general corporate news announcement, especially one distributed via a news service like EQS, typically falls under a general regulatory announcement or news release category. Since it is not a formal financial report, earnings release, or a specific corporate action like a dividend or share transaction, the most appropriate general category is Regulatory Filings (RNS), which serves as a fallback for miscellaneous regulatory announcements not covered by other specific codes.
2022-10-25 English
EQS-DD: BRAIN Biotech AG english
Director's Dealing Classification · 100% confidence The document is explicitly titled 'Directors’ Dealings' and contains detailed information regarding a transaction ('Acquisition') by a 'person discharging managerial responsibilities' (Dr. Georg Kellinghusen, Member of the administrative or supervisory body) in the company's shares (BRAIN Biotech AG). This directly matches the definition for Director's Dealing (DIRS). The structure and content are typical of insider transaction disclosures.
2022-10-13 English
EQS-DD: BRAIN Biotech AG english
Director's Dealing Classification · 100% confidence The document is explicitly titled 'Directors’ Dealings' and contains detailed information regarding transactions (Acquisition) of shares by a 'person discharging managerial responsibilities' (Michael Schneiders, Member of the managing body) in BRAIN Biotech AG. This directly matches the definition for Director's Dealing, which corresponds to the filing code DIRS.
2022-10-13 English
EQS-DD: BRAIN Biotech AG english
Director's Dealing Classification · 100% confidence The document is explicitly titled 'Directors’ Dealings' and contains a section detailing 'Notification and public disclosure of transactions by persons discharging managerial responsibilities'. It lists the name of an individual (Michael Schneiders), their position ('Member of the managing body'), the nature of the transaction ('Acquisition'), the financial instrument (Share), and the date and price of the transaction. This content directly matches the definition for Director's Dealing (DIRS). The document length is short, but the content is the primary disclosure itself, not an announcement of a report.
2022-10-13 English
EQS-DD: BRAIN Biotech AG english
Director's Dealing Classification · 100% confidence The document is explicitly titled 'Directors’ Dealings' and contains a section titled 'Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them'. It details the name of an individual (Michael Schneiders), their position ('Member of the managing body'), the nature of the transaction ('Acquisition'), the financial instrument (Share), and the price/volume details. This content directly matches the definition for Director's Dealing (DIRS). The document length is short, but the content is the primary disclosure itself, not an announcement of a report.
2022-10-13 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.